Novo Nordisk said it is now planning to advance both subcutaneous and oral formulations of amycretin into additional clinical trials. The new data follows another study that showed the ...

D rug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

as well as the launches of Mim8 and amycretin. What do I expect from Eli Lilly in the long term? I estimate Eli Lilly's non-GAAP EPS and revenue growth will be higher than Novo Nordisk's over the ...

Novo Nordisk shares have dropped ~50% since June ... Despite strong market share and promising early results for Amycretin, competition from Eli Lilly and regulatory risks pose significant challenges.

The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved ... vice president for Development at Novo Nordisk. "The results seen in the trial ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD ... adding that even if CagriSema is a commercial failure, the firm’s amycretin program (that could enter phase 3 this ...

Novo Nordisk NVO shares have lost 15.2% so far ... In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in ...